811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, B-G. Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro
Topics & Concepts
MedicineOlaparibInternal medicineProgression-free survivalOvarian cancerRandomizationOncologyChemotherapyUrologyCancerGastroenterologySurgeryRandomized controlled trialGenePoly ADP ribose polymeraseChemistryPolymeraseBiochemistryPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies